Présentation de l'entreprise
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic medicines designed for the treatment of cancer. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, which typically involves high levels of research and development expenditure prior to commercial product launch. At its current scale, the organization maintains a market capitalization of $776.42M, generates annual revenue of $67.48M, and employs a workforce of 260 individuals. These valuation and revenue figures indicate that the company holds a significant market presence despite being in a pre-revenue or early commercialization phase, suggesting substantial investor confidence in the potential of its pipeline assets such as KOMZIFTI and Darlifarnib.
Santé financière
The financial performance metrics for the trailing twelve months reveal a revenue of $67.48M, a net income of $-278,665,984, and an EBITDA of $-302,599,008. The substantial negative gap between the $67.48M in revenue and the $-278,665,984 in net income highlights a cost structure where operating expenses, likely driven by clinical trial costs and R&D, significantly exceed total sales. The company reports a free cash flow of $-141,728,368, which indicates a consumption of cash reserves to fund operations and development activities rather than generating surplus liquidity. The margin analysis shows a gross margin of -272.1%, an operating margin of -497.6%, and a profit margin of 0.0%, figures that reflect the typical economics of a biotech firm where high fixed costs and regulatory expenditures result in losses before achieving commercial profitability. Regarding balance sheet strength, the company holds $667.24M in cash against $20.46M in debt, supported by a debt-to-equity ratio of 11.75. Although the debt-to-equity ratio appears high numerically, the overwhelming cash position suggests a conservative stance toward leverage relative to available liquid assets. The current ratio stands at 6.06, indicating a very strong ability to meet short-term obligations with current assets. Return on Equity is reported at -94.8% and Return on Assets at -25.3%, metrics that reveal management is currently deploying capital to grow the enterprise value rather than generating immediate shareholder returns through profit.
Évaluation de la valorisation
Valuation multiples for Kura Oncology, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -3.60, implying that the market does not yet price in positive earnings but rather anticipates future profitability or values the company based on asset potential. The price-to-book ratio is 4.43, which indicates that the stock trades at a significant premium over its net asset value, a common characteristic for companies with valuable intellectual property and pipeline assets. Alternative valuation metrics show a price-to-sales ratio of 11.51 and an EV/EBITDA of -0.43, suggesting that the market values the company based on revenue generation potential rather than current earnings power or cash flow. The 52-week trading range spans from a low of $5.45 to a high of $12.49, placing the current valuation within a specific band relative to these historical extremes. The beta value of 0.24 indicates that the stock exhibits low volatility relative to the broader market, moving with significantly less intensity than the S&P 500 index.
Growth & Income
The growth metrics display a revenue growth year-over-year of -67.8% and earnings growth year-over-year of N/A, illustrating that the company is currently contracting in terms of top-line sales as it transitions from clinical trials to commercialization or adjusts its market strategy. Since the earnings growth is not applicable due to negative earnings, the relationship between revenue contraction and profitability remains consistent with the company's loss-making status. As the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically reinvested into growth initiatives, though currently, the firm burns cash to sustain its development efforts. The overall growth and income profile is characterized by negative revenue growth and a complete absence of dividend income, reflecting the strategic priority placed on advancing the clinical pipeline over immediate shareholder distribution.